Dementia in Parkinson's disease;Demens ved Parkinsons sykdom

Tidsskrift for den Norske Laegeforening

Volumn 127, Issue 19, 2007, Pages 2517-2520

  Halvorsen, Øystein ^a   Tysnes, Ole Bjørn ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

AGED; COGNITIVE DEFECT; DEMENTIA; HUMAN; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR;

AGED; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 35448962377     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-63.
2. Levy G, Tang MX, Louis ED et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708-13.
3. Aarsland D, Larsen JP, Tandberg E et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-42.
4. Aarsland D. Demens med Lewy-legemer. Tidsskr Nor Lægeforen 2002; 122: 525-9
5. Aarsland D, Larsen JP, Karlsen K et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-74.
6. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1043-9.
7. Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson's disease: a communitybased, prospective study. Neurology 2001; 56: 730-6.
8. Foltynie T, Brayne CE, Robbins TW et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
9. Janvin C, Aarsland D, Larsen JP et al. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003; 15: 126-31.
10. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149-54.
11. Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
12. Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61: 1906-11.
13. Levy G, Schupf N, Tang MX et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51: 722-9.
14. Burn DJ, Rowan EN, Allan LM et al. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-9.
15. Levy G. Dementia in Parkinson's disease challenges the «gold standard». Ann Neurol 2005; 58: 663-5.
16. Burton EJ, McKeith IG, Burn DJ et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127: 791-800.
17. Apaydin H, Ahlskog JE, Parisi JE et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: 102-12.
18. Aarsland D, Perry R, Brown A et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58: 773-6.
19. Antonini A, De Notaris R, Benti R et al. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci 2001; 22: 45-6.
20. Rinne JO, Rummukainen J, Paljarvi L et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989; 26: 47-50.
21. Jellinger KA, Paulus W. Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg 1992; 94 (suppl): S86-8.
22. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 2003; 18 (suppl 6): S63-71.
23. Ito K, Nagano-Saito A, Kato T et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125: 1358-65.
24. Piggott MA, Ballard CG, Dickinson HO et al. Thalamic D 2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. Int J Neuropsychopharmacol 2007; 10: 231-44.
25. Hilker R, Thomas AV, Klein JC et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-22.
26. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006: CD004747.
27. Dubois B, Danze F, Pillon B et al. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987; 22: 26-30.
28. Janvin CC, Larsen JP, Salmon DP et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 2006; 21: 337-42.
29. Mosimann UP, Mather G, Wesnes KA et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004; 63: 2091-6.
30. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17: 137-45.
31. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13: 844-51.
32. Tandberg E, Larsen JP, Aarsland D et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53: 175-9.
33. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17: 164-71.
34. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
35. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-9.
36. Maidment ID, Fox C, Boustani M. A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia. Acta Psychiatr Scand 2005; 111: 403-9.
37. Kulisevsky J, Garcia-Sanchez C, Berthier ML et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15: 613-26.
38. Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001; 16 (suppl 1): S12-18.
39. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005; 20 (suppl 12): S77-82.